Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT).

Chou JF, Kernan NA, Prockop S, Heller G, Scaradavou A, Kobos R, Knowles MA, Papadopoulos EB, Casson A, Copeland C, Torok-Castanza J, Zakak N, Ruggiero J, Small TN.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1708-13. doi: 10.1016/j.bbmt.2011.05.006. Epub 2011 May 23.

2.

Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation.

Sasadeusz J, Prince HM, Schwarer A, Szer J, Stork A, Bock HL, Povey M, Nicholson O, Innis BL.

Transpl Infect Dis. 2014 Dec;16(6):1024-31. doi: 10.1111/tid.12295. Epub 2014 Oct 1.

PMID:
25272081
3.

Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.

Aoki T, Koh K, Kawano Y, Mori M, Arakawa Y, Kato M, Hanada R.

Biol Blood Marrow Transplant. 2016 Apr;22(4):771-775. doi: 10.1016/j.bbmt.2015.12.025. Epub 2015 Dec 31.

4.

Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.

Leung TF, Li CK, Hung EC, Chan PK, Mo CW, Wong RP, Chik KW.

Eur J Haematol. 2004 May;72(5):353-7.

PMID:
15059071
5.

Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs.

Kussmaul SC, Horn BN, Dvorak CC, Abramovitz L, Cowan MJ, Weintrub PS.

Bone Marrow Transplant. 2010 Nov;45(11):1602-6. doi: 10.1038/bmt.2010.31. Epub 2010 Mar 1.

PMID:
20190839
6.

The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children.

Taweesith W, Puthanakit T, Kowitdamrong E, Bunupuradah T, Wongngam W, Phasomsap C, Apornpong T, Bouko C, Pancharoen C.

Pediatr Infect Dis J. 2011 Apr;30(4):320-4. doi: 10.1097/INF.0b013e3181fe0868.

PMID:
20975615
7.

A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella.

Gershon AA, Levin MJ, Weinberg A, Song LY, LaRussa PS, Steinberg SP, Bartlett P; Pediatric AIDS Clinical Trials Group 391 Team.

Pediatr Infect Dis J. 2009 Jul;28(7):653-5. doi: 10.1097/INF.0b013e3181998f06.

8.

Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants.

Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, Arvin AM.

N Engl J Med. 2002 Jul 4;347(1):26-34.

9.

Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients.

Kawano Y, Suzuki M, Kawada J, Kimura H, Kamei H, Ohnishi Y, Ono Y, Uchida H, Ogura Y, Ito Y.

Vaccine. 2015 Mar 17;33(12):1440-5. doi: 10.1016/j.vaccine.2015.01.075. Epub 2015 Feb 7.

PMID:
25665961
10.

Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study.

Ljungman P, Wang FZ, Nilsson C, Solheim V, Linde A.

Support Care Cancer. 2003 Nov;11(11):739-41. Epub 2003 Sep 17.

PMID:
13680325
11.

Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients.

Issa NC, Marty FM, Leblebjian H, Galar A, Shea MM, Antin JH, Soiffer RJ, Baden LR.

Biol Blood Marrow Transplant. 2014 Feb;20(2):285-7. doi: 10.1016/j.bbmt.2013.11.013. Epub 2013 Nov 22.

12.

Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants.

Jaffe D, Papadopoulos EB, Young JW, O'reilly RJ, Prockop S, Kernan NA, Jakubowski A, Boulad F, Perales MA, Castro-Malaspina H, Small TN.

Blood. 2006 Oct 1;108(7):2470-5. Epub 2006 Jun 8.

15.

Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.

Parment PA, Svahn A, Rudén U, Bråkenhielm G, Storsaeter J, Akesson L, Linde A.

Scand J Infect Dis. 2003;35(10):736-42.

PMID:
14606613
16.

Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation.

Mahler MB, Taur Y, Jean R, Kernan NA, Prockop SE, Small TN.

Biol Blood Marrow Transplant. 2012 Jan;18(1):145-9. doi: 10.1016/j.bbmt.2011.07.027. Epub 2011 Aug 4.

17.

Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months.

Ramkissoon A, Coovadia HM, Jugnundan P, Haffejee IE, Meurice F, Vandevoorde D.

S Afr Med J. 1995 Dec;85(12):1295-8.

PMID:
8600589
18.

A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.

Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, Heineman TC.

J Infect Dis. 2012 Oct;206(8):1280-90. Epub 2012 Aug 7.

PMID:
22872734
19.

Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells.

Levin MJ, Gershon AA, Weinberg A, Song LY, Fentin T, Nowak B; Pediatric AIDS Clinical Trials Group 265 Team.

J Infect Dis. 2006 Jul 15;194(2):247-55. Epub 2006 Jun 14.

PMID:
16779732
20.

Supplemental Content

Support Center